{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962793",
  "id": "02962793",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250627",
  "time": "0929",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5ftngmx0ghm.pdf",
  "summary": "**Key Material Information:**  \n\n- **Acquisition Completed**: NSB has acquired 100% of Isopogen WA, gaining rights to the **StemSmart\u2122 Stem Cell technology**.  \n- **Capital Position**: Post-placement, **cash on hand ~$7.5M**.  \n- **Clinical Focus**: Special Access Program (SAS) for **fistulising Crohn\u2019s disease** commenced; target market **$13.8B by 2026**.  \n- **Phase 2 Trial Data**: Early results show StemSmart\u2122 MSC therapy is **potent, efficacious, and safe** in refractory Crohn\u2019s (18 patients, majority improved/remission).  \n- **Board Changes**: New appointments (Robert McKenzie as Chair, Paul Fry as director); issued **10M options at $0.07** (3-year expiry).  \n\n*Excluded*: Forward-looking statements, operational history, non-material director comments.",
  "usage": {
    "prompt_tokens": 1691,
    "completion_tokens": 195,
    "total_tokens": 1886,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:54:27.866187"
}